Clinical Trial Update: Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating mirvetuximab soravtansine in combination with bevacizumab, carboplatin, pegylated liposomal doxorubicin, or pembrolizumab for FRα-p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Fallopian Tube Cancer
• Peritoneal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• Mirvetuximab soravtansine (mirvetuximab soravtansine)
• Pegylated liposomal doxorubicin (pegylated liposomal doxorubicin)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: ImmunoGen, Inc. | Conditions: Epithelial Ovarian Cancer, Primary Peritoneal Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-02-14